Elina Tea joins Theratechnologies board and audit committee

MONTREAL - Theratechnologies (NASDAQ:THTX) Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical firm specializing in innovative therapy development, today announced Elina Tea's appointment to its Board of Directors.

Tea, currently the Chief Financial Officer at GLS North America, will also serve on the company's Audit Committee as Investissement Québec's designee, following their investor rights agreement.

Tea's background includes a wealth of experience in finance, corporate strategy, and investor relations. Her previous roles have spanned various industries, involving significant work in private and public financing, mergers and acquisitions, and business development.

She has held positions at Vosker Corp, Cogeco Communications, and has experience from SNC-Lavalin, Desjardins Group, RBC Capital Markets, and Ernst & Young Corporate Finance. Tea is a Chartered Financial Analyst and holds a Bachelor of Commerce degree from McGill University.

Dawn Svoronos, Chair of the Board at Theratechnologies, praised Tea's strong communication and strategic thinking skills, as well as her leadership capabilities. Svoronos expressed confidence that Tea's diverse experience will support the company's business initiatives and contribute valuable perspectives as the company focuses on expanding its commercial business and seeking new products and partnerships.

Tea expressed her honor in joining Theratechnologies' Board and her eagerness to contribute to the company's success and value creation. With her addition, the Audit Committee now includes four independent members: Jordan Zwick, Gerald Lacoste, Frank Holler as Chair, and Tea.

Theratechnologies is known for addressing unmet medical needs through its development and commercialization of innovative therapies. The company's growth and search for new products and partners are part of its strategic direction.

This announcement is based on a press release statement from Theratechnologies. The company cautions investors not to place undue reliance on forward-looking statements contained in the press release, as actual results may vary. These statements are based on management's current beliefs and assumptions, which are subject to risks and uncertainties that could cause actual outcomes to differ materially.

As Theratechnologies Inc. (NASDAQ: THTX) welcomes Elina Tea to its Board of Directors, investors are closely monitoring the company's financial health and stock performance. According to InvestingPro data, Theratechnologies currently has a market capitalization of approximately $65.75 million.

Get The App

Join the millions of people who stay on top of global financial markets with Investing.com.

Download Now

Despite the company's efforts in innovation and expansion, analysts have recently adjusted their earnings expectations downward for the upcoming period, signaling caution among the investment community.

InvestingPro Tips indicate that Theratechnologies' stock has experienced significant volatility, with a notable decline over the last week. This could be attributed to the broader market conditions or company-specific factors.

Analysts are also not expecting the company to be profitable this year, which may be a point of concern for potential investors. Additionally, the company has not been profitable over the last twelve months and does not pay a dividend to shareholders, which might influence investment decisions for those seeking immediate returns or income.

For investors looking to dive deeper into Theratechnologies' financials and stock performance, InvestingPro offers additional insights and metrics. There are more InvestingPro Tips available for Theratechnologies, providing a comprehensive analysis of the company's prospects. Interested readers can access these tips by visiting https://www.investing.com/pro/THTX and can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.